Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation

Date

22 Nov 2020

Session

e-Poster Display Session

Presenters

Yoshihiko Taniguchi

Citation

Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367

Authors

Y. Taniguchi1, T. Yamada2, A. Yoshimura2, H. Taniguchi3, K. Kaira4, S. Atagi5, S. Yano6, K. Takayama2

Author affiliations

  • 1 Internal Medicine, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 2 Pulmonary Medicine, Kyoto Prefectural University of Medicine, 602-8566 - Kyoto/JP
  • 3 Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki/JP
  • 4 Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama/JP
  • 5 Department Of Thoracic Oncology, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 6 Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa/JP
More

Abstract 411P

Background

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated non-small cell lung cancer (NSCLC). However, some patients show intrinsic resistance and an insufficient response to osimertinib. Increased expression of the anexelekto (AXL) protein in tumors is reported to be associated with poor prognosis in patients with several types of cancer. We previously reported the crucial role of the AXL pathway in the intrinsic resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Moreover, AXL overexpression in EGFR-mutated NSCLC specimens was negatively associated with the therapeutic efficacy of first- and second-generation EGFR-TKIs. However, the relationship between AXL expression in tumors and the therapeutic efficacy of osimertinib is still unclear.

Methods

We retrospectively enrolled 30 patients with advanced or relapsed NSCLC with EGFR-activating mutations from four institutions in Japan. All patients were administered osimertinib as the first-line treatment between August 2017 and March 2019.

Results

Twenty-two (73.3%) patients were female; 21 (70.0%) patients had never smoked. The median age of patients was 71.0 years (range, 44–88 years of age). The EGFR-activating mutations were deletion in exon 19 in 16 (53.3%) patients; L858R missense mutation in exon 21 in 12 (40.0%) patients; and other types in 2 (6.6%) patients. High (3+), intermediate (2+), low (1+), and no (0) pre-treatment expression of AXL in tumors was observed in 2 (6.7%), 4 (13.3%), 12 (40.0%), and 12 (40.0%) patients, respectively. The maximal tumor shrinkage rate following osimertinib treatment in the patients with AXL expression scores of 0 and 1+ was higher than that in patients with AXL expression scores of 2+ and 3+ (44.12% vs. 25.93%, p = 0.094).

Conclusions

Pre-treatment AXL expression in tumors may be a promising predictor of osimertinib treatment efficacy in patients with EGFR-mutated NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

T. Yamada: Research grant/Funding (self): Pfizer Inc.; Research grant/Funding (self): Ono Pharmaceutical Co., Ltd; Research grant/Funding (self): Chugai Pharmaceutical Co., Ltd; Research grant/Funding (self): Takeda Pharmaceutical Co., Ltd. S. Atagi: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Ono; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squib; Honoraria (self): Hisamitsu; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (institution): F. Hoffmann-La Roche. K. Takayama: Honoraria (self), Research grant/Funding (self): Chugai-Roche Co.; Research grant/Funding (self): Ono Pharmaceutical Co.; Honoraria (self): AstraZeneca Co.; Honoraria (self): MSD-Merck Co.; Honoraria (self): Eli Lilly Co.; Honoraria (self): Boehringer-Ingelheim Co.; Honoraria (self): Daiichi-Sankyo Co. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.